The trial demonstrates that a swallowable, low-pill, non-absorbed iron polymer can match or exceed sevelamer in phosphate ...

Research Highlight Published: 01 June 2006 Sevelamer for treating hyperphosphatemia in pediatric CKD patients Rachael Williams Nature Clinical Practice Nephrology 2, 296 (2006) Cite this article ...

The global hyperphosphatemia treatment market grew from $3.57 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the ...

In this video, Kevin Martin, MD, discusses treatment options available to patients with hyperphosphatemia.

Increasing product launches and approval of novel drugs in key regions around the globe are expected to fuel the global hyperphosphatemia drugs market growth in the near future. For instance, in 2016, ...

In this video, Kevin Martin, MD, discusses new and emerging technologies in the field of hyperphosphatemia.

Red meat, long acclaimed for its richness in protein, iron and vitamin B12, is now at the heart of numerous debates concerning its effects on health. A Scottish study published in the journal Aging ...

About Hyperphosphatemia Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD).

Key Takeaways from the Market Study The global hyperphosphatemia market is expected to reach US$ 20.24 billion by 2033, growing at a CAGR of 4.8%. Iron-based phosphate binder is expected to grab 20% ...

Major players in the hyperphosphatemia treatment market are Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, Akebia Therapeutics, Inc, Vifor Pharma Management Ltd. , Lupin Limited, ...